Lynparza Rejection Highlights ‘Two-Tier’ Funding Problem In UK
Too Many Uncertainties, Price Not Justified, Says NICE
Executive Summary
Health technology assessment body NICE has said that Lynparza from AstraZeneca and MSD is not a cost-effective use of National Health Service resources in England for prostate cancer patients at the price at which it is currently being offered. AZ and NICE say they will try to reach an agreement.